Literature DB >> 32484380

Time for a Paradigm Shift in Head and Neck Cancer Management During the COVID-19 Pandemic.

Albert Y Han1, Jessa E Miller1, Jennifer L Long1,2,3,4, Maie A St John1,2,3.   

Abstract

OBJECTIVE: The coronavirus disease 2019 (COVID-19) pandemic has caused physicians and surgeons to consider restructuring traditional cancer management paradigms. We aim to review the current evidence regarding the diagnosis and management of head and neck cancer, with an emphasis on the role of the multidisciplinary team (MDT) during a pandemic. DATA SOURCES: COVID-19 resources from PubMed, Google Scholar, the American Academy of Otolaryngology-Head and Neck Surgery, and the American Head and Neck Society were examined. REVIEW
METHODS: Studies and guidelines related to the multidisciplinary management of head and neck cancer in the COVID-19 setting were reviewed. A total of 54 studies were included. Given the continuously evolving body of literature, the sources cited include the latest statements from medical and dental societies.
RESULTS: The unpredictable fluctuation of hospital resources and the risk of the nosocomial spread of SARS-CoV-2 have direct effects on head and neck cancer management. Using an MDT approach to help define "essential surgery" for immediately life- or function-threatening disease processes in the context of available hospital resources will help to maximize outcomes. Early enrollment in an MDT is often critical for considering nonsurgical options to protect patients and health care workers. The role of the MDT continues after cancer treatment, if delivered, and the MDT plays an essential role in surveillance and survivorship programs in these challenging times.
CONCLUSION: Head and neck cancer management during the COVID-19 pandemic poses a unique challenge for all specialists involved. Early MDT involvement is important to maximize patient outcomes and satisfaction in the context of public and community safety.

Entities:  

Keywords:  COVID-19; cancer management; head and neck cancer; multidisciplinary cancer; survivorship

Mesh:

Year:  2020        PMID: 32484380      PMCID: PMC7484111          DOI: 10.1177/0194599820931789

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  52 in total

Review 1.  When should surveillance imaging be performed after treatment for head and neck cancer?

Authors:  Thomas E Heineman; Edward C Kuan; Maie A St John
Journal:  Laryngoscope       Date:  2017-02-10       Impact factor: 3.325

2.  Association of Clinical Risk Factors and Postoperative Complications With Unplanned Hospital Readmission After Head and Neck Cancer Surgery.

Authors:  Andrés M Bur; Jason A Brant; Carolyn L Mulvey; Elizabeth A Nicolli; Robert M Brody; John P Fischer; Steven B Cannady; Jason G Newman
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2016-12-01       Impact factor: 6.223

3.  Telemedicine in otolaryngology outpatient setting-single Center Head and Neck Surgery experience.

Authors:  Ryan A Rimmer; Vanessa Christopher; Ailsa Falck; Edmund de Azevedo Pribitkin; Joseph M Curry; Adam J Luginbuhl; David M Cognetti
Journal:  Laryngoscope       Date:  2018-02-15       Impact factor: 3.325

Review 4.  COVID-19 and the Otolaryngologist: Preliminary Evidence-Based Review.

Authors:  Neelaysh Vukkadala; Z Jason Qian; F Christopher Holsinger; Zara M Patel; Eben Rosenthal
Journal:  Laryngoscope       Date:  2020-04-24       Impact factor: 3.325

5.  Impact of multidisciplinary team management in head and neck cancer patients.

Authors:  P L Friedland; B Bozic; J Dewar; R Kuan; C Meyer; M Phillips
Journal:  Br J Cancer       Date:  2011-03-29       Impact factor: 7.640

Review 6.  Head and neck surgical oncology in the time of a pandemic: Subsite-specific triage guidelines during the COVID-19 pandemic.

Authors:  Anastasios Maniakas; Yelda Jozaghi; Mark E Zafereo; Erich M Sturgis; Shirley Y Su; Ann M Gillenwater; Paul W Gidley; Carol M Lewis; Eduardo Diaz; Ryan P Goepfert; Michael E Kupferman; Neil D Gross; Amy C Hessel; Kristen B Pytynia; Marc-Elie Nader; Jennifer R Wang; Miriam N Lango; Kimberley L Kiong; Theresa Guo; Xiao Zhao; Christopher M K L Yao; Eric Appelbaum; Jennifer Alpard; Jose A Garcia; Shawn Terry; Jill E Flynn; Sarah Bauer; Danielle Fournier; Courtlyn G Burgess; Cayla Wideman; Matthew Johnston; Chenxi You; Rolando De Luna; Liza Joseph; Julia Diersing; Kaitlin Prescott; Katherine Heiberger; Lilian Mugartegui; Jessica Rodriguez; Sara Zendehdel; Justin Sellers; Rebekah A Friddell; Ajay Thomas; Sonam J Khanjae; Katherine B Schwarzlose; Mark S Chambers; Theresa M Hofstede; Richard C Cardoso; Ruth Aponte Wesson; Alex Won; Adegbenga O Otun; Dan S Gombos; Nagham Al-Zubidi; Katherine A Hutcheson; G Brandon Gunn; David I Rosenthal; Maura L Gillison; Renata Ferrarotto; Randal S Weber; Ehab Y Hanna; Jeffrey N Myers; Stephen Y Lai
Journal:  Head Neck       Date:  2020-06       Impact factor: 3.147

7.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

Authors:  Chaolin Huang; Yeming Wang; Xingwang Li; Lili Ren; Jianping Zhao; Yi Hu; Li Zhang; Guohui Fan; Jiuyang Xu; Xiaoying Gu; Zhenshun Cheng; Ting Yu; Jiaan Xia; Yuan Wei; Wenjuan Wu; Xuelei Xie; Wen Yin; Hui Li; Min Liu; Yan Xiao; Hong Gao; Li Guo; Jungang Xie; Guangfa Wang; Rongmeng Jiang; Zhancheng Gao; Qi Jin; Jianwei Wang; Bin Cao
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

8.  Online mental health services in China during the COVID-19 outbreak.

Authors:  Shuai Liu; Lulu Yang; Chenxi Zhang; Yu-Tao Xiang; Zhongchun Liu; Shaohua Hu; Bin Zhang
Journal:  Lancet Psychiatry       Date:  2020-02-19       Impact factor: 27.083

9.  SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China.

Authors:  Jing Yu; Wen Ouyang; Melvin L K Chua; Conghua Xie
Journal:  JAMA Oncol       Date:  2020-07-01       Impact factor: 31.777

10.  Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention.

Authors:  Zunyou Wu; Jennifer M McGoogan
Journal:  JAMA       Date:  2020-04-07       Impact factor: 56.272

View more
  8 in total

Review 1.  New Challenges of Treatment for Locally Advanced Head and Neck Cancers in the Covid-19 Pandemic Era.

Authors:  Camil Ciprian Mireștean; Anda Crișan; Adina Mitrea; Călin Buzea; Roxana Irina Iancu; Dragoș Petru Teodor Iancu
Journal:  J Clin Med       Date:  2021-02-04       Impact factor: 4.241

2.  Effect of coronavirus disease 2019 on recurrences and follow up of head and neck squamous cell carcinoma.

Authors:  E Kytö; E Haapio; I Kinnunen; H Irjala
Journal:  J Laryngol Otol       Date:  2021-03-23       Impact factor: 1.469

3.  The impact of COVID-19 on head and neck cancer diagnosis and disease extent.

Authors:  Kimberley L Kiong; Edward M Diaz; Neil D Gross; Eduardo M Diaz; Ehab Y Hanna
Journal:  Head Neck       Date:  2021-03-02       Impact factor: 3.821

4.  The Impact of COVID-19 on Head and Neck Cancer Treatment: Before and During the Pandemic.

Authors:  Roberto N Solis; Mehrnaz Mehrzad; Samya Faiq; Roberto P Frusciante; Harveen K Sekhon; Marianne Abouyared; Arnaud F Bewley; D Gregory Farwell; Andrew C Birkeland
Journal:  OTO Open       Date:  2021-12-23

5.  Rehabilitation Needs of Head and Neck Cancer Patients and Stakeholders: Case Study.

Authors:  Maria Karampela; Talya Porat; Vasiliki Mylonopoulou; Minna Isomursu
Journal:  Front Oncol       Date:  2021-09-24       Impact factor: 6.244

6.  COVID-19 and head and neck oncology.

Authors:  Deepa Danan
Journal:  Oper Tech Otolayngol Head Neck Surg       Date:  2022-04-28

7.  Effects of the COVID-19 Pandemic on Head and Neck Cancer Stage and Treatment Duration.

Authors:  Savvas Kourtidis; Julia Münst; Veit M Hofmann
Journal:  Cureus       Date:  2022-07-11

8.  Delayed presentation of head and neck cancer patients during COVID-19 pandemic.

Authors:  Fırat Tevetoğlu; Sinem Kara; Chinara Aliyeva; Rafet Yıldırım; H Murat Yener
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-03-06       Impact factor: 2.503

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.